Jump to content

Farampator

From Wikipedia, the free encyclopedia
Farampator
Clinical data
Other namesCX-691; ORG-24448
Legal status
Legal status
Identifiers
  • 2,1,3-benzoxadiazol-6-yl-piperidin-1-ylmethanone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H13N3O2
Molar mass231.255 g·mol−1
3D model (JSmol)
  • C1CCN(CC1)C(=O)C2=CC3=NON=C3C=C2
  • InChI=1S/C12H13N3O2/c16-12(15-6-2-1-3-7-15)9-4-5-10-11(8-9)14-17-13-10/h4-5,8H,1-3,6-7H2 ☒N
  • Key:XFVRBYKKGGDPAJ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Farampator (developmental code names CX-691, ORG-24448, SCH-900460) is an ampakine drug. It was developed by Cortex Pharmaceuticals, and licensed to Organon BioSciences for commercial development. Following the purchase of Organon by Schering-Plough in 2007, the development license to farampator was transferred. The development of farampator was eventually terminated, reportedly due to concerns about cardiac toxicity.[1][2]

Farampator has been investigated for its effect on AMPA receptors and researched for potential use in the treatment of schizophrenia and Alzheimer's disease. It was found to improve short-term memory, but impaired episodic memory. It produced side effects such as headache, somnolence and nausea. Subjects reporting side effects had significantly higher plasma levels of farampator than subjects without.[citation needed] Additional analyses revealed that in the farampator condition the group without side effects showed a significantly superior memory performance relative to the group with side effects.[3]

See also

[edit]

References

[edit]
  1. ^ "Farampator - AdisInsight".
  2. ^ Froestl W, Muhs A, Pfeifer A (2012). "Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors". J. Alzheimers Dis. 32 (4): 793–887. doi:10.3233/JAD-2012-121186. PMID 22886028.
  3. ^ Wezenberg E, Verkes RJ, Ruigt GS, Hulstijn W, Sabbe BG (Jun 2007). "Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers". Neuropsychopharmacology. 32 (6): 1272–83. doi:10.1038/sj.npp.1301257. PMID 17119538.